With the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis.
British researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.
Every year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?
Mark Beards is the new CEO of Sutura Therapeutics Ltd in Birkenhead (UK).
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
Following the completion of Danahers €19.5bn take-over of GE Healthcare Life Sciences, GEs CDMO arm is renamed Cytiva.
In October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.
Austrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients